GUEST COLUMNISTS

• Controls For Retrieval-Augmented Generation In GxP

  Validation teams deal with inherent variability all the time. The same principles for GMP — think visual inspection — can apply to probabilistic AI systems.

• Implementing AI Solutions In GMP While Managing Risk

  When using artificial intelligence in GMP settings, risk management extends far beyond  validation. This discussion explores moving AI solutions out of the pilot phase.

• Implementing And Optimizing Your eQMS

  This article addresses everything that follows the signed contract for an eQMS: how a system is configured, validated, adopted, and maintained.

• A Much-Improved Approach For Understanding And Managing Safety Risks

  Learn how causal mechanism and effect analysis (CMEA) and its principles can be used to develop and maintain safer working environments in the pharma/biotech and medical device industries.

• CSV Assumes The AI System Sits Still — It Doesn't.

  The computer system validation playbook was written for software that holds its shape. AI doesn't. Validating it has to become an act of governance.

• July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing

  Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.

• In Bioprocessing, Trusted Data Is A Process Variable

  As digital systems become increasingly interconnected, digital validation ensures systems generating and managing GxP data remain accurate, consistent, and trustworthy.